Interaction between m6A methylation and noncoding RNA in glioma.

Area of Science:

• Neuro-oncology
• Epigenetics
• RNA biology

Background:

• Glioma is the most common primary brain tumor, characterized by aggressive growth and high recurrence rates, leading to poor patient prognosis.
• The precise etiology of glioma remains largely unknown, highlighting the need for deeper understanding of its molecular mechanisms.
• N6-methyladenosine (m6A) methylation, a crucial reversible RNA modification, plays a significant role in various biological processes.

Purpose of the Study:

• To review the expression and function of common m6A regulators in glioma.
• To elucidate the intricate interplay between m6A regulators and noncoding RNAs (ncRNAs) in glioma progression.
• To provide insights into potential therapeutic targets within the m6A-ncRNA axis for glioma treatment.

Main Methods:

• Literature review of recent studies on m6A regulators and ncRNAs in glioma.
• Analysis of reported data on the expression patterns of m6A regulators in glioma tissues.
• Synthesis of findings on the functional roles of m6A regulators and ncRNAs in glioma pathogenesis.

Main Results:

• Aberrant expression of m6A regulators has been observed in glioma, correlating with tumor progression.
• m6A regulators influence glioma development, partly through their interactions with ncRNAs.
• ncRNAs, as key epigenetic regulators, can modulate the function of m6A regulators in the context of glioma.

Conclusions:

• The m6A methylation pathway and its regulators are significantly implicated in glioma.
• The reciprocal interactions between m6A regulators and ncRNAs are critical in driving glioma progression.
• Targeting the m6A-ncRNA axis presents a promising avenue for future glioma therapies.